All In Biotech

Drug Trial Radar · NCT05139719

A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients

A Phase IIb, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With Progressive Fibrosing Interstitial Lung Disease

Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Feb 15, 2023

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Sunshine Lake Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of this phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing interstitial lung diseases. This study is divided into two stages, i.e. main study stage with 24 weeks treatment duration followed by up to 96 weeks treatment extended study stage.

Conditions

  • Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

Interventions

  • HEC585 dose ADrug

    taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage

  • HEC585 dose BDrug

    taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage

  • PlaceboDrug

    taking Placebo orally once daily, up to 24 weeks in main stage

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 24 in FVC (mL) compared with placeboTime frame: 24 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.